Key Takeaways:
- Eli Lilly shares rose 5.35% on continued GLP-1 momentum
- Novo Nordisk gained 5.24% as oral Wegovy attracts new patients
- The obesity drug sector rallied broadly amid bullish demand outlook
Back
Eli Lilly and Novo Nordisk surge 5% as weight-loss drug sector rallies
Eli Lilly and Novo Nordisk each surged more than 5% Thursday, leading a broad rally in weight-loss drug stocks.
"The GLP-1 market continues to expand beyond expectations, with oral formulations opening a new patient demographic," said Sam Goldstein, healthcare analyst at Edgen.
Eli Lilly (LLY) rose 5.35%, extending its 12-month gain past 45%. The Indianapolis-based drugmaker became the first $1 trillion pharmaceutical company late last year, powered by its GLP-1 franchise including Zepbound and Mounjaro. Novo Nordisk (NVO) gained 5.24%, recovering from a 68% decline over the past two years as competition from Lilly's Zepbound and clinical setbacks for its next-generation drug CagriSema weighed on the stock.
The rally shows investor conviction that obesity treatment demand will remain a multi-hundred-billion-dollar opportunity. Lilly forecasts 2026 revenue of $82 billion to $85 billion, up 28% at the midpoint, while Novo Nordisk's oral Wegovy pill is drawing a wave of new patients who had avoided injectable therapies.
Lilly's Pipeline Expansion
Lilly has invested aggressively to extend its lead. On May 26, the company announced $3.83 billion in acquisitions spanning three biotech firms, including $1.5 billion for Curevo's shingles vaccine candidate and $1.55 billion for the Vaccine Company's Epstein-Barr virus program. In April, it spent $2.3 billion on Ajax Therapeutics for rare blood cancer therapies. The company has 42 phase 3 trials and 32 phase 2 trials underway.
Novo Nordisk's Turnaround Bets
Novo Nordisk is fighting back with a deep pipeline. Its oral semaglutide (Wegovy pill) has proven popular among patients who preferred not to use injections. The company is advancing Amycretin, a single-molecule GLP-1/amylin agonist now in phase 3 studies, and UBT251, a triple-target gut hormone agonist that showed promising phase 2 results in China. These candidates could help the Danish drugmaker reclaim market share lost to Lilly's Zepbound.
Broader Market Context
The sector rally occurred alongside a broader market advance. The S&P 500 added 0.2%, while the Dow Jones Industrial Average climbed 841 points, or 1.7%. The Russell 2000 index of small-cap stocks jumped 1.4% as Treasury yields eased, with the 10-year yield falling to 4.46%.
The dual surge signals that investors see both companies benefiting from the expanding obesity market rather than a zero-sum contest. For Lilly, the key catalyst is its ability to scale manufacturing and maintain its efficacy edge. For Novo Nordisk, the oral Wegovy launch and Amycretin data due in the coming quarters will determine whether it can close the gap. Both stocks remain sensitive to clinical trial readouts and pricing dynamics in the US market.
This article is for informational purposes only and does not constitute investment advice.
